CN115282078A

CN115282078A - Full-effect eye cream and preparation method thereof

Info

Publication number: CN115282078A
Application number: CN202211047298.2A
Authority: CN
Inventors: 孙云起; 聂艳峰; 王娟; 郭朝万; 蒲艳; 胡露
Original assignee: Guangdong Marubi Biological Technology Co Ltd
Current assignee: Guangdong Marubi Biological Technology Co Ltd
Priority date: 2022-08-29
Filing date: 2022-08-29
Publication date: 2022-11-04
Anticipated expiration: 2042-08-29
Also published as: CN115282078B

Abstract

The invention provides a full-effect eye cream and a preparation method thereof, wherein the full-effect eye cream comprises, by mass, 40-60% of water, 0.5-2% of a first mixture and 10-30% of a second mixture. The full-effect eye cream provided by the invention is mild in formula, and the components are matched with each other and synergized, so that the moisture content of the horny layer of the eye, the transdermal moisture loss amount, the skin glossiness and the skin elasticity are improved, the MI value of the melanin content of the skin of the lower eyelid is reduced, the fishtail lines are reduced, the fine lines under the eye are reduced, the R1 value of the roughness of the fine lines under the eye is reduced, the R1 value of the roughness of the fishtail lines is reduced, the area of the fine lines under the eye is reduced, the fishtail line area is reduced, and the under-eye bags and the corners of the eyes are improved. And the manufacturing process is simple, environment-friendly and convenient to use.

Description

Full-effect eye cream and preparation method thereof

Technical Field

The invention belongs to the technical field of skin care products, and particularly relates to a full-effect eye cream and a preparation method thereof.

Background

The eye skin is the thinnest skin of a human body, sweat glands and sebaceous glands of the skin around the eyes are rarely distributed, elastic fibers and collagen structures are lacked in a dermis layer, nerve fibers and capillary vessels of the skin around the eyes are high in distribution density, and the eye work load is heavy; and as the age increases, lymph and blood circulation becomes slower, blood reflux is insufficient, making the skin darker around the eye and possibly causing hemoglobin to accumulate in the connective tissue, forming dark circles.

CN110368355A discloses an astaxanthin-containing nanoemulsion anti-aging eye cream and a preparation method thereof, which comprises the following components in percentage by mass: 3-5 parts of honey, 3-5 parts of self-made astaxanthin extract, 4-6 parts of modified nano pearl powder, 2-4 parts of lily essential oil, 3-5 parts of tea saponin, 10-15 parts of natural oil, 5-10 parts of milk, 40-55 parts of water, 0.4-1.7 parts of aloe powder, 2-3 parts of glutathione and 3-5 parts of glycerol. The prepared eye cream has high astaxanthin content, good skin absorption rate, excellent oxidation resistance and wrinkle resistance and high safety.

CN105287320A discloses a mild firming and repairing eye cream and a preparation method thereof, wherein the eye cream comprises: retinol palmitate, palmitoyl oligopeptide, further preferred eye creams include: retinol palmitate, palmitoyl oligopeptide, radix astragali extract, rhizoma Atractylodis Macrocephalae extract, and radix Altaicae extract. The composition has good effects of removing skin wrinkles and the like, is added into a matrix to prepare eye cream, and has mild, compact and repairing effects on the skin of eyes; it also has good stability.

The eye care products disclosed in the prior art mainly have the following defects: (1) the eye care product has relatively single effect, or moisturizes eyes, reduces eye bags, fades dark circles, or improves wrinkles, all the effects cannot be considered simultaneously, and the eye care product is deficient in all-round improvement of eye problems; (2) although the eye cream can quickly take effect, after the eye cream is used for a period of time, side effects are easy to generate, or new problems such as fat particles are brought about, and the eye burden is increased.

Based on the above, there is a need to develop a mild, safe, fast-acting, highly effective eye cream which can moisturize and comprehensively solve the eye problems.

Disclosure of Invention

Aiming at the defects of the prior art, the invention aims to provide a full-effect eye cream and a preparation method thereof. The full-effect eye cream provided by the invention is mild in formula, and the components are matched with each other and synergized, so that the moisture content of the horny layer of the eye, the transdermal moisture loss amount, the skin glossiness and the skin elasticity are improved, the MI value of the melanin content of the skin of the lower eyelid is reduced, the fishtail lines are reduced, the fine lines under the eye are reduced, the R1 value of the roughness of the fine lines under the eye is reduced, the R1 value of the roughness of the fishtail lines is reduced, the area of the fine lines under the eye is reduced, the fishtail line area is reduced, and the under-eye bags and the corners of the eyes are improved.

In order to achieve the purpose, the invention adopts the following technical scheme:

in a first aspect, the present invention provides a full-effect eye cream comprising, by mass percent, 40-60% (e.g., can be 40%, 42%, 46%, 48%, 50%, 52%, 54%, 56%, 58%, 60%, etc.) water, 0.5-2% (e.g., can be 0.5%, 0.7%, 1%, 1.3%, 1.5%, 1.7%, 2%, etc.) of a first mixture, and 10-30% (e.g., can be 10%, 13%, 16%, 19%, 23%, 26%, 29%, 30%, etc.) of a second mixture;

the first mixture comprises arginine/lysine polypeptide, dextran, glycerol, polyglycerol-10 diisostearate, polyglycerol-10 laurate, 1, 2-hexanediol, ethylhexylglycerol, butylene glycol, p-hydroxyacetophenone, sodium citrate, citric acid, and water;

the second mixture comprises oligopeptide-1, acetyl tetrapeptide-5, arginine/lysine polypeptide, beta-alanyl hydroxyproline diaminobutyric acid benzylamine, palmitoyl pentapeptide-4, acetyl hexapeptide-8, PPG-13-decyltetradecanol polyether-24, water, 1, 2-pentanediol, and 1, 2-hexanediol.

In the present invention, the first mixture comprises ZPC-019S and the second mixture comprises MAX-Peptide.

Preferably, the full-effect eye cream further comprises, by mass percent, 1-3% (e.g., may be 1%, 1.2%, 1.4%, 1.6%, 1.8%, 2%, 2.2%, 2.4%, 2.6%, 2.8%, 3%, etc.), hydrogenated lecithin 0.3-1% (e.g., may be 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, etc.), behenyl alcohol 1-3% (e.g., may be 1%, 1.2%, 1.4%, 1.6%, 1.8%, 2%, 2.2%, 2.4%, 2.6%, 2.8%, 3%, etc.), glycerol triesters of C10-18 fatty acids 0.5-1.5% (e.g., may be 0.5%, 0.7%, 0.9%, 1.1%, 1.3%, 1.5%, etc.), and dimethicone 1-2% (e.g., may be 1%, 1.4%, 1.8%, etc.);

the third mixture includes a C14-22 alcohol, a C12-20 alkyl glucoside, water, and glucose.

Preferably, the third mixture comprises Montanov L.

In the present invention, the full-effect eye cream further includes, by mass percentage, 1 to 3% (e.g., may be 1%, 1.2%, 1.4%, 1.6%, 1.8%, 2%, 2.2%, 2.4%, 2.6%, 2.8%, 3%, etc.), squalane 1 to 3% (e.g., may be 1%, 1.2%, 1.4%, 1.6%, 1.8%, 2%, 2.2%, 2.4%, 2.6%, 2.8%, 3%, etc.), ubiquinone 0.005 to 0.02% (e.g., may be 0.005%, 0.007%, 0.009%, 0.01%, 0.013%, 0.015%, 0.017%, 0.02%, etc.), tocopherol acetate 0.3 to 0.6% (e.g., may be 0.3%, 0.4%, 0.5%, 0.6%, etc.), sodium hyaluronate 0.01 to 0.05% (e.g., may be 0.01%, 0.02%, 0.03%, 0.04%, 0.9%, 3.9%, 3% and 7%, etc.), glycerol 1 to 3% (e.9%, etc.).

In the present invention, the full-effect eye cream further includes, by mass percentage, 3 to 6% of glycerin (e.g., may be 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, etc.), 0.005 to 0.03% of disodium EDTA (e.g., may be 0.005%, 0.007%, 0.009%, 0.01%, 0.013%, 0.015%, 0.017%, 0.02%, 0.022%, 0.025%, 0.027%, 0.03%, etc.), 0.05 to 0.2% of dipotassium glycyrrhizinate (e.g., may be 0.05%, 0.07%, 0.1%, 0.12%, 0.14%, 0.16%, 0.18%, 0.2%, etc.), and 0.1 to 0.3% of acrylic/C10-30 alkanol acrylate crosspolymer (e.g., may be 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, etc.).

In the present invention, the full-effect eye cream further includes, by mass percentage, 0.5 to 1% (e.g., may be 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, etc.), 0.1 to 0.15% (e.g., may be 0.1%, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%, etc.), 0.1 to 0.3% (e.g., may be 0.1%, 0.13%, 0.16%, 0.2%, 0.23%, 0.26%, 0.3%, etc.), 2 to 3% (e.g., may be 2%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3%, etc.) of a fourth mixture, and 0.05 to 0.2% (e.05%, 0.15%, 0.2%, etc.) of a sixth mixture;

the fourth mixture comprises hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, polyisobutylene, PEG-7 trimethylolpropane coco ether, water and sorbitan isostearate;

the fifth mixture comprises 1, 2-hexanediol and octanediol;

the sixth mixture includes water, glycerin, sodium dihydrogen phosphate, disodium hydrogen phosphate, and soluble collagen.

Preferably, the fourth mixture comprises SEPIPLUS and the fifth mixture comprises SEPIPLUS

68, the sixth mixture comprises a fully human source ^TM Collagen protein.

In the present invention, the full-effect eye cream further includes, by mass percentage, 0.2 to 0.5% of a seventh mixture (e.g., 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, etc.), 0.001 to 0.003% of neroli oil (e.g., 0.001%, 0.0015%, 0.002%, 0.0025%, 0.003%, etc.), 0.005 to 0.12% of chamomile oil (e.g., 0.005%, 0.01%, 0.05%, 0.1%, 0.12%, etc.), and 1 to 3% of an eighth mixture (e.g., 1%, 1.5%, 2%, 2.5%, 3%, etc.);

said seventh mixture comprising water, 1, 3-propanediol, and saffron extract;

the eighth mixture includes water, acetyl tetrapeptide-5, and butylene glycol.

Preferably, the seventh mixture comprises SENS' FLOWER SD-SC, and the eighth mixture comprises

peptide solution B。

In the present invention, the full-effect eye cream comprises, by mass, 40 to 60% of water, 0.5 to 2% of a first mixture, 10 to 30% of a second mixture, 1 to 3% of a third mixture, 0.3 to 1% of hydrogenated lecithin, 1 to 3% of behenyl alcohol, 0.5 to 1.5% of triglyceride of C10-18 fatty acid, 1 to 2% of polydimethylsiloxane, 1 to 3% of meadowfoam seed oil, 1 to 3% of squalane, 0.005 to 0.02% of ubiquinone, 0.3 to 0.6% of tocopherol acetate, 0.01 to 0.05% of sodium hyaluronate, 0.5 to 3% of glyceryl polyether-26, 3 to 6% of glycerin, 0.005 to 0.03% of disodium EDTA, 0.05 to 0.2% of dipotassium glycyrrhizinate, 0.1 to 0.3% of (acrylate)/C10 to 30% of alkanol acrylate crosspolymer, 0.5 to 1% of a fourth mixture, 0.1 to 0.15% of aminomethyl propanol, 0.1 to 0.3% of a fifth mixture, 1,2 to 0.3% of 1% of pentanediol, 0.05 to 0.3% of a sixth mixture, 0.05 to 0.003% of chrysanthemum oil, 0.1 to 0.3% of a seventh mixture, 0.003% of orange oil, 0.7 to 0.3% of a mixture, and 0.003% of a mixture;

wherein the first mixture comprises arginine/lysine polypeptide, dextran, glycerol, polyglycerol-10 diisostearate, polyglycerol-10 laurate, 1, 2-hexanediol, ethylhexylglycerol, butylene glycol, p-hydroxyacetophenone, sodium citrate, citric acid, and water;

the second mixture comprises oligopeptide-1, acetyl tetrapeptide-5, arginine/lysine polypeptide, beta-alanyl hydroxyproline diaminobutyric acid benzylamine, palmitoyl pentapeptide-4, acetyl hexapeptide-8, PPG-13-decyltetradecanol polyether-24, water, 1, 2-pentanediol, and 1, 2-hexanediol;

the third mixture comprises a C14-22 alcohol, a C12-20 alkyl glucoside, water, and glucose;

the fifth mixture comprises 1, 2-hexanediol and octanediol;

the sixth mixture comprises water, glycerin, sodium dihydrogen phosphate, disodium hydrogen phosphate, and soluble collagen;

said seventh mixture comprises water, 1, 3-propanediol, and saffron extract;

the eighth mixture includes water, acetyl tetrapeptide-5, and butylene glycol.

Preferably, the first blend comprises ZPC-019S, the second blend comprises MAX-Peptide, the third blend comprises Montanov L, the fourth blend comprises SEPIPLUS, and the fifth blend comprises SEPIPLUS

68, the sixth mixture comprises a fully human source ^TM Collagen, the seventh mixture comprising SENS' FLOWER SD-SC, the eighth mixture comprising

peptide solution B。

In a second aspect, the present invention provides a method for preparing a full-effect eye cream according to the first aspect, the method comprising the steps of:

and mixing water, ZPC-019S and MAX-Peptide to obtain the double-effect eye cream.

In the invention, the preparation method of the full-effect eye cream specifically comprises the following steps:

(1) Mixing the third mixture, hydrogenated lecithin, behenyl alcohol, triglycerides of C10-18 fatty acids, polydimethylsiloxane, meadowfoam seed oil, squalane, ubiquinone and tocopherol acetate, and stirring to obtain an oil phase;

mixing water, sodium hyaluronate, glyceryl polyether-26, glycerin, EDTA disodium, dipotassium glycyrrhizinate and acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer, and stirring to obtain water phase;

(2) Mixing the oil phase and the water phase obtained in the step (1), performing primary high-speed homogenization, adding a fourth mixture and aminomethyl propanol, and performing secondary high-speed homogenization to obtain a water-oil mixture;

(3) And (3) mixing the water-oil mixture obtained in the step (2), the fifth mixture, 1, 2-pentanediol, the sixth mixture, the seventh mixture, the neroli oil, the chamomile oil, the eighth mixture, the first mixture and the second mixture, and stirring to obtain the double-effect eye cream.

In the present invention, in the step (1), in the operation of obtaining the oil phase, the temperature of the stirring is 80 to 85 ℃ (for example, 80 ℃, 81 ℃, 82 ℃, 83 ℃, 84 ℃, 85 ℃ and the like may be used).

Preferably, in the step (1), the temperature of the stirring in the operation of obtaining the aqueous phase is 80 to 85 ℃ (for example, 80 ℃, 81 ℃, 82 ℃, 83 ℃, 84 ℃, 85 ℃ and the like may be possible).

Preferably, in the step (2), the temperature of the first high-speed homogenization and the second high-speed homogenization are respectively and independently 80-85 ℃ (for example, 80 ℃, 81 ℃, 82 ℃, 83 ℃, 84 ℃, 85 ℃ and the like), and the rotation speed is respectively and independently 2000-3000rpm (for example, 2000rpm, 2100rpm, 2200rpm, 2300rpm, 2400rpm, 2500rpm, 2600rpm, 2700rpm, 2800rpm, 2900rpm, 3000rpm and the like).

Preferably, in the step (3), the stirring temperature is 44-46 ℃ (for example, 44 ℃, 44.5 ℃, 45 ℃, 45.5 ℃, 46 ℃ and the like can be used).

Compared with the prior art, the invention has the following beneficial effects:

the full-effect eye cream provided by the invention is mild in formula, and the components are mutually matched and synergized, so that the moisture content of the horny layer of the eye is jointly improved, the transdermal moisture loss is reduced, the skin glossiness is improved, the skin elasticity is improved, the MI value of the melanin content of the skin of the lower eyelid is reduced, the fishtail lines are reduced, the fine lines under the eye are reduced, the roughness R1 value of the fine lines under the eye is reduced, the roughness R1 value of the fishtail lines is reduced, the area of the fine lines under the eye is reduced, the fishtail line area is reduced, and the under-eye bags and the canthus are improved. And the manufacturing process is simple, environment-friendly and convenient to use.

Drawings

FIG. 1 is a graph showing the trend of change in the moisture content of the horny layer;

wherein, represents p <0.05, represents p <0.01, and represents p <0.001.

FIG. 2 shows the rate of change of the moisture content of the horny layer.

FIG. 3 is a graph showing the change of the amount of percutaneous water loss;

wherein, represents p <0.05, represents p <0.01, and represents p <0.001.

FIG. 4 is the rate of change of transdermal water loss.

FIG. 5 is a graph showing the variation trend of skin glossiness;

wherein, represents p <0.05, represents p <0.01, and represents p <0.001.

FIG. 6 is a graph of skin gloss change rate.

FIG. 7 is a graph showing the trend of the change in the R2 value of the skin elasticity;

wherein denotes p <0.05, denotes p <0.01, and denotes p <0.001.

FIG. 8 is a graph showing the rate of change in the R2 value of the skin elasticity.

FIG. 9 is a graph showing the change of MI value of melanin content in skin;

wherein, represents p <0.05, represents p <0.01, and represents p <0.001.

FIG. 10 shows the change rate of MI value of skin melanin content.

Fig. 11 is a diagram of the variation trend of the fine lines Sew under the eyes;

wherein, represents p <0.05, represents p <0.01, and represents p <0.001.

Fig. 12 shows the rate of change of the fine lines Sew under the eyes.

Fig. 13 is a graph showing the variation trend of the fishtail line SEw;

wherein, represents p <0.05, represents p <0.01, and represents p <0.001.

Fig. 14 shows the rate of change of the crow's feet SEw.

FIG. 15 is a graph showing the variation trend of the roughness R1 of the fine lines under the eyes;

wherein, represents p <0.05, represents p <0.01, and represents p <0.001.

Fig. 16 shows the rate of change in the value of the under-eye fine line roughness R1.

FIG. 17 is a graph showing the variation trend of the roughness R1 value of the fishtail line;

wherein, represents p <0.05, represents p <0.01, and represents p <0.001.

Fig. 18 shows the rate of change in the value of the crow's foot roughness R1.

FIG. 19 is a graph showing the variation of the area of fine lines under the eyes;

wherein, represents p <0.05, represents p <0.01, and represents p <0.001.

Fig. 20 is the rate of change of the area of fine lines under the eye.

FIG. 21 is a graph showing the variation trend of the crow's feet area;

wherein, represents p <0.05, represents p <0.01, and represents p <0.001.

Fig. 22 shows the rate of change in the area of the fishtail line.

FIG. 23 is a diagram of the trend of pouch changes;

wherein, represents p <0.05, represents p <0.01, and represents p <0.001.

Fig. 24 is the change rate of the pouch score.

FIG. 25 is a graph of the trend of the canthus score;

wherein denotes p <0.05, denotes p <0.01, and denotes p <0.001.

Fig. 26 is a graph of the change rate of the canthus score.

Detailed Description

The technical solution of the present invention is further explained by the following embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitations of the present invention.

The sources of the components in the following examples are as follows:

example 1

The embodiment provides a full-effect eye cream which comprises the following components in parts by weight:

the preparation method comprises the following steps:

(1) Mixing the third mixture, hydrogenated lecithin, behenyl alcohol, triglycerides of C10-18 fatty acids, polydimethylsiloxane, meadowfoam seed oil, squalane, ubiquinone and tocopherol acetate, and stirring to obtain an oil phase; the stirring temperature is 83 ℃;

mixing water, sodium hyaluronate, glyceryl polyether-26, glycerin, EDTA disodium, dipotassium glycyrrhizinate and acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer, and stirring to obtain water phase; the stirring temperature is 83 ℃;

(2) Mixing the oil phase and the water phase obtained in the step (1), performing primary high-speed homogenization, adding a fourth mixture and aminomethyl propanol, and performing secondary high-speed homogenization to obtain a water-oil mixture; the temperature of the primary high-speed homogenization and the secondary high-speed homogenization are both 83 ℃, and the rotating speed is both 2500rpm;

(3) Mixing the water-oil mixture obtained in the step (2), a fifth mixture, 1, 2-pentanediol, a sixth mixture, a seventh mixture, neroli oil, chamomile oil, an eighth mixture, the first mixture and the second mixture, and stirring to obtain the double-effect eye cream; the temperature of the stirring was 45 ℃.

Example 2

the preparation method comprises the following steps:

(1) Mixing the third mixture, hydrogenated lecithin, behenyl alcohol, triglycerides of C10-18 fatty acids, polydimethylsiloxane, meadowfoam seed oil, squalane, ubiquinone and tocopherol acetate, and stirring to obtain an oil phase; the stirring temperature is 80 ℃;

mixing water, sodium hyaluronate, glyceryl polyether-26, glycerin, EDTA disodium, dipotassium glycyrrhizinate and acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer, and stirring to obtain water phase; the stirring temperature is 80 ℃;

(2) Mixing the oil phase and the water phase obtained in the step (1), performing primary high-speed homogenization, adding a fourth mixture and aminomethyl propanol, and performing secondary high-speed homogenization to obtain a water-oil mixture; the temperature of the primary high-speed homogenization and the secondary high-speed homogenization are both 80 ℃, and the rotating speed is both 3000rpm;

(3) Mixing the water-oil mixture obtained in the step (2), a fifth mixture, 1, 2-pentanediol, a sixth mixture, a seventh mixture, neroli oil, chamomile oil, an eighth mixture, the first mixture and the second mixture, and stirring to obtain the double-effect eye cream; the temperature of the stirring was 44 ℃.

Example 3

The implementation provides a full-effect eye cream which comprises the following components in parts by weight:

the preparation method comprises the following steps:

(1) Mixing the third mixture, hydrogenated lecithin, behenyl alcohol, triglycerides of C10-18 fatty acids, polydimethylsiloxane, meadowfoam seed oil, squalane, ubiquinone and tocopherol acetate, and stirring to obtain an oil phase; the stirring temperature is 85 ℃;

mixing water, sodium hyaluronate, glyceryl polyether-26, glycerin, EDTA disodium, dipotassium glycyrrhizinate and acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer, and stirring to obtain water phase; the stirring temperature is 85 ℃;

(2) Mixing the oil phase and the water phase obtained in the step (1), performing primary high-speed homogenization, adding a fourth mixture and aminomethyl propanol, and performing secondary high-speed homogenization to obtain a water-oil mixture; the temperature of the primary high-speed homogenization and the temperature of the secondary high-speed homogenization are both 85 ℃, and the rotating speed is both 2000rpm;

(3) Mixing the water-oil mixture obtained in the step (2), the fifth mixture, 1, 2-pentanediol, the sixth mixture, the seventh mixture, the neroli oil, the chamomile oil, the eighth mixture, the first mixture and the second mixture, and stirring to obtain the double-effect eye cream; the temperature of the stirring was 46 ℃.

Example 4

This example provides a full-effect eye cream, which is different from example 1 only in that squalane is replaced by chinaroot greens seed oil in the same weight part, and other components and preparation methods are the same as example 1.

Example 5

This example provides a full-effect eye cream, which is different from example 1 only in that squalane is replaced by the same weight part of meadowfoam seed oil, and other components and preparation methods are the same as example 1.

Example 6

This example provides a full-effect eye cream, which is different from example 1 only in that the neroli oil is replaced by the same weight parts of chamomile oil, and the other components and preparation method are the same as example 1.

Example 7

This example provides a full-effect eye cream, which is different from example 1 only in that the mother chrysanthemum oil is replaced by the orange flower oil in the same weight part, and other components and preparation methods are the same as example 1.

Comparative example 1

This comparative example provides a full-effect eye cream, which differs from example 1 only in that the first mixture is replaced by an equal part by weight of the second mixture, and the other ingredients and preparation method are the same as example 1.

Comparative example 2

This comparative example provides a full-effect eye cream, which differs from example 1 only in that the second mixture is replaced with the same parts by weight of the first mixture, and the other ingredients and preparation method are the same as example 1.

Test example 1

The test method comprises the following steps: 30 Chinese healthy female subjects with dry and rough skin, loose skin, black eye and under-eye bags are selected, and the age range is 35-60 years. The examinee uses the product eye cream on the whole face and massages the eye cream by matching with the product massage head. The test product is used before a test product is used by a subject, the test product is used continuously for 7 days, the test product is used continuously for 14 days, and the test product is used continuously for 28 days, so that the moisture content of the horny layer of the eye corner, the moisture loss through the skin, the skin glossiness and the skin elasticity are measured, the skin melanin content MI value of the lower eyelid, the fishtail line, the fine line under the eye, the roughness R1 value of the fishtail line, the area of the fine line under the eye, the area of the fishtail line, the eye pouch and the eye corner are analyzed, the eye corner and the eye pouch of the subject are visually evaluated by 3 visual sensation evaluators, the subject performs self evaluation according to an investigation questionnaire, and the data result and the evaluation result before and after the product is used are compared through a statistical test method so as to judge whether the statistical difference exists.

Detecting the environment: the test environment is at 20.5-21.8 deg.C and 43.8-56.4% RH, and meets the requirement of scheme design.

Test samples: the full-effect eye cream provided in example 1.

And (3) detecting a result by an instrument: and performing descriptive statistics on various measured values by using EXCEL software, wherein the statistics comprise quantity, mean value, standard deviation, minimum value, maximum value and the like.

And (3) applying SPSS analysis software, performing significance Test on data improvement value normal distribution by adopting Shapiro-Wilk Test, wherein if Sig. (double sides) >0.01 shows normal distribution, performing pairing t Test, and taking significance difference level p as 0.05. If sig. (two-sided) <0.01, then it is non-normally distributed, wilcoxon test is performed, and the level of significant difference p is taken to be 0.05.

Delta difference = post-use data mean-pre-use data mean;

rate of change after product use by individual (%) = (data after personal use-data before personal use)/data before personal use;

the rate of change (%) in the following test was (sum of individual rates of change)/total number of persons.

In the following tests, the significance labeling method is denoted: "n.s." means no statistical difference, p >0.05; "+" indicates significant difference, p is more than or equal to 0.01 and less than 0.05, "+" indicates significant difference, p is more than or equal to 0.001 and less than 0.01; "x" indicates significant difference, p <0.001.

1.1 sub-ocular stratum corneum moisture content test

Comparative data before and after use of stratum corneum moisture content are shown in table 1 below:

TABLE 1

The results of the statistical analysis of the water content of the horny layer are shown in the following table 2:

TABLE 2

As shown in table 1, table 2, fig. 1 and fig. 2, after 7 days of continuous use of the test product, the moisture content of the stratum corneum under the eyes of the subjects was significantly increased by 20.68% (p < 0.001); after 14 days of continuous use of the test product, the water content of the stratum corneum of the eyes of the subjects is remarkably improved by 25.15% (p < 0.001); after 28 days of continuous use of the test product, the water content of the stratum corneum of the eyes of the subjects is remarkably increased by 25.87 percent (p is less than 0.001); as shown above, the test product can be used for 7 days, 14 days and 28 days continuously, so that the water content of the stratum corneum under the eyes can be obviously improved, and the moisturizing effect is achieved.

1.2 amount of sub-ocular percutaneous Water loss

Comparative data before and after use of transdermal water loss are shown in table 3 below:

TABLE 3

The results of the statistical analysis of the transdermal water loss are shown in the following table 4:

TABLE 4

As shown in table 3, table 4, fig. 3 and fig. 4, subjects had a significant improvement in sub-ocular transdermal water loss of 0.95% (absolute) (p < 0.01) after 7 days of continuous use of the test product; after 14 days of continuous use of the test product, the subcutaneous transdermal water loss of the subject was significantly improved by 3.97% (absolute) (p < 0.001); after 28 days of continuous use of the test product, the subjects showed a significant improvement in cheek transdermal water loss of 14.88% (absolute) (p < 0.001); as shown above, the continuous use of the test product for 7 days, 14 days and 28 days can obviously improve the subcutaneous water loss and has the effect of improving the skin barrier function.

1.3 skin gloss on the outside of the canthus

Skin gloss comparative data before and after use are shown in table 5 below:

TABLE 5

The results of the statistical analysis of skin gloss are shown in table 6 below:

TABLE 6

As shown in table 5, table 6, fig. 5 and fig. 6, the skin gloss was significantly improved by 15.63% (p < 0.001) on the outer canthus side of the subject after 7 days of continuous use of the test product; after 14 days of continuous use of the test product, the skin gloss on the outer canthus of the tested person is remarkably improved by 16.20% (p is less than 0.001); after the test product is continuously used for 28 days, the skin gloss on the outer canthus of the eyes of the testee is remarkably improved by 16.82 percent (p is less than 0.001); as shown above, the test products are continuously used for 7 days, 14 days and 28 days, so that the skin glossiness of the outer side of the canthus can be obviously improved, and the skin gloss effect is achieved.

1.4 sub-ocular skin elasticity R2 value

Skin elasticity R2 values the comparative data before and after use are shown in table 7 below:

TABLE 7

The results of a statistical analysis of the R2 values for skin elasticity are shown in Table 8 below:

TABLE 8

As can be seen from the data in table 7, table 8, fig. 7 and fig. 8, the R2 value of the skin elasticity under the eyes of the subjects was significantly increased by 7.21% (p < 0.01) after the test products were continuously used for 7 days; after the test product is continuously used for 14 days, the R2 value of the skin elasticity under the eyes of the testee is remarkably improved by 13.00 percent (p is less than 0.01); after 28 days of continuous use of the test product, the R2 value of the skin elasticity under eyes of the subject is significantly improved by 14.53 percent (p is less than 0.01); as shown above, the test product can be continuously used for 7 days, 14 days and 28 days, the under-eye skin elasticity R2 value can be obviously improved, and the effect of improving the skin elasticity is achieved.

1.5 Melanin content MI value of lower eyelid skin

Comparative data before and after use of the skin melanin content MI values are shown in table 9 below:

TABLE 9

The MI values of skin melanin content were analyzed statistically as shown in table 10 below:

watch 10

As shown in table 9, table 10, fig. 9 and fig. 10, no significant improvement in MI values of melanin content in the skin of the lower eyelid of the subject was observed after 7 days of continuous use of the test product; after 14 days of continuous use of the test product, the subject's lower eyelid skin melanin content MI was significantly improved by 4.4% (absolute) (p < 0.01); after 28 days of continuous use of the test product, the subjects had a significant improvement in the MI value of the melanin content of the lower eyelid skin of 4.81 (absolute) (p < 0.01); as shown above, the MI value of the melanin content of the skin of the lower eyelid can be obviously improved by continuously using the test product for 14 days and 28 days, and the MI value has the effects of light black eye circles and improvement of the vascular reaction effect of the black eye circles.

1.6 fine lines Sew under the eyes

The comparative data before and after use for the sub-ocular fine line Sew are shown in Table 11 below:

TABLE 11

The results of the statistical analysis of the fine lines Sew under the eyes are shown in the following Table 12:

TABLE 12

As shown in table 11, table 12, fig. 11, and fig. 12, the fine lines Sew under the eyes of the subjects were significantly improved by 3.87% (absolute value) after 7 days of continuous use of the test products; after 14 days of continuous use of the test product, the fine lines Sew under the eyes of the subjects were significantly improved by 4.97% (absolute) (p < 0.05); after 28 days of continuous use of the test product, the fine lines Sew under the eyes of the subjects were significantly improved by 5.83% (absolute) (p < 0.001); as described above, the test products were continuously used for 7 days, 14 days, and 28 days, and the fine lines ew (improved number of fine lines) under the eyes were significantly improved, which had the effect of fading the fine lines under the eyes.

1.7 fishtail line

The before and after use ratio of the crow's feet Sew is shown in the following Table 13:

watch 13

The results of the statistical analysis of the crow's feet Sew are shown in Table 14 below:

TABLE 14

As can be seen from the data in table 13, table 14, fig. 13 and fig. 14, the fishtail line Sew of the subjects improved by 1.46% (absolute) after 7 days of continuous use of the test products; after 14 days of continuous use of the test product, the subjects showed a significant improvement of the crow's feet Sew of 3.73% (absolute) (p < 0.01); after 28 days of continuous use of the test product, the fine lines Sew under the eyes of the subjects were significantly improved by 3.77% (absolute) (p < 0.001); as described above, the test product was used continuously for 14 days and 28 days, and the crow's feet Sew (improvement in the number of wrinkles) was significantly improved, and the crow's feet was reduced.

1.8 Undereye Fine line roughness R1 value

The under-eye line roughness R1 values are shown in Table 15 below using pre-and post-application comparative data:

watch 15

The R1 values of the fine line roughness under the eyes were statistically analyzed and the results are shown in Table 16 below:

TABLE 16

As shown in table 15, table 16, fig. 15, and fig. 16, the fine line roughness R1 value under the eyes of the subjects was improved by 1.39% (absolute value) after 7 days of continuous use of the test products; after 14 days of continuous use of the test product, the undereye fine line roughness R1 value of the test subjects improved by 3.50% (absolute) (p < 0.05); after 28 days of continuous use of the test product, the R1 value of the fine line roughness under the eyes of the subjects was improved by 5.66% (absolute) (p < 0.001); as described above, the test product was used continuously for 14 days and 28 days, and the roughness R1 value of the fine lines under the eyes (improvement of the depth of the fine lines) was significantly improved, which had the effect of reducing the fine lines under the eyes.

1.9 fishtail roughness R1 value

Comparative data before and after use of the fishtail roughness R1 values are shown in Table 17 below:

TABLE 17

The results of the statistical analysis of the R1 values of fishtail roughness are shown in table 18 below:

watch 18

As shown in table 17, table 18, fig. 17 and fig. 18, the subject's fishtail roughness R1 value improved by 0.25% (absolute) after 7 days of continuous use of the test product; after 14 days of continuous use of the test product, the subject's crow's feet R1 value improved by 2.65% (absolute); after 28 days of continuous use of the test product, the subject's crow's feet R1 improved by 4.13% (absolute) (p < 0.01); as shown above, the test product can be used for 28 days continuously, the roughness R1 value of the fishtail lines can be obviously improved (the fine line depth is improved), and the fishtail line fading effect is achieved.

1.10 area of fine lines under the eye

Comparative data before and after use for the fine line area under the eye are shown in table 19 below:

watch 19

The results of the statistical analysis of the area of fine lines under the eyes are shown in table 20 below:

watch 20

As shown in table 19, table 20, fig. 19, and fig. 20, the fine line area under the eyes of the subjects improved by 0.2% (absolute value) after 7 days of continuous use of the test products; after 14 days of continuous use of the test product, the area of fine lines under the eyes of the subject improved by 3.93% (absolute); after 28 days of continuous use of the test product, the area of fine lines under the eyes of the subjects improved by 6.10% (absolute) (p < 0.01); as described above, the test product was used continuously for 28 days, and the fine lines under the eyes were significantly improved in area (improvement of wrinkle area), and had the effect of lightening the fine lines under the eyes.

1.11 area of fishtail line

Comparative data before and after the fishtail area is used are shown in the following table 21:

TABLE 21

The results of statistical analysis of the crow's feet area are shown in table 22 below:

TABLE 22

As shown in table 21, table 22, fig. 21, and fig. 22, the subjects showed a 5.44% (absolute) improvement in crow's foot area after 7 days of continuous use of the test product; after 14 days of continuous use of the test product, the subject's crow's feet area improved by 9.19% (absolute); after 28 days of continuous use of the test product, the subjects showed a significant improvement in crow's feet area of 10.69% (absolute) (p < 0.01); as shown above, the test product can be used for 28 days continuously, the fishtail line area can be obviously improved (fine line depth is improved), and the fishtail line fading effect is achieved.

1.12 expert evaluation-eye bags

The moisture content of the skin at 2.5mm was tested.

Comparative data before and after pouch use are shown in table 23 below:

TABLE 23

The pouch analysis results are shown in table 24 below:

watch 24

As shown in table 23, table 24, fig. 23 and fig. 24, the subjects had an improvement in the pouches of 0.71% (absolute value) after 7 days of continuous use of the test products; after 14 days of continuous use of the test product, the pouch of the subject improved by 3.45% (absolute) (p < 0.01); after 28 days of continuous use of the test product, the pouch of the subject was significantly improved by 9.23% (absolute) (p < 0.01); as shown above, the continuous use of the test product for 14 days and 28 days can obviously improve the bags under the eyes and has the effect of lightening the bags under the eyes.

1.13 visual assessment-canthus

Comparative pre-and post-use data for the canthus are shown in table 25 below:

the test method comprises the following steps: a moving scale with the length of 10cm is used, the two ends are respectively a 0 minute end and a 10 minute end, forward evaluation is carried out, the 0 minute shows that the effect is very poor, the 10 minute shows that the effect is very good, and the lifting effect of the canthus is more obvious when the score is higher.

TABLE 25

The canthus analysis results are shown in table 26 below:

watch 26

As shown in table 25, table 26, fig. 25, and fig. 26, the canthus of the subjects was significantly increased by 15.34% (p < 0.001) after 7 days of continuous use of the test products; after the test product is continuously used for 14 days, the canthus of the tested person is obviously improved by 22.54 percent (p is less than 0.001); after 28 days of continuous use of the test product, the canthus of the tested person is obviously improved by 25.41 percent (p is less than 0.001); as described above, the canthus can be remarkably improved by continuously using the test product for 7 days, 14 days and 28 days, and the canthus lifting effect is achieved.

Test example two

Test samples: examples 1-7 and comparative examples 1-2 provide full-effect eye creams.

The test method comprises the following steps: 90 Chinese healthy female testees with dry and rough skin, loose skin, black eye and eye bags are selected, the age range is 35-60 years old, 9 groups are adopted, each group is respectively tested with one sample, and the testees use the product eye cream on the whole face and are matched with the product massage heads for massage. The skin gloss, skin elasticity and the lower eyelid skin melanin content MI values were performed on the outside of the canthus 28 days before the test product was used by the subjects and the product was used in conjunction.

2.1 skin gloss on the outside of the canthus

The skin gloss change rate on the outer canthus after 28 days of the product combination is shown in table 27 below:

watch 27

As can be seen from the comparison of examples 1, 4 to 7 and comparative examples 1 to 2, squalane, meadowfoam seed oil, chamomile oil, neroli oil, the first mixture and the second mixture cooperate with each other to synergistically enhance the skin gloss on the outside of the canthus.

2.2 sub-ocular skin elasticity R2 value

The rate of change in the skin elasticity R2 values under the eyes after 28 days of the combination product is shown in table 28 below:

watch 28

As can be seen from the comparison among examples 1, 4 to 7 and comparative examples 1 to 2, squalane, meadowfoam seed oil, chamomile oil, neroli oil, the first mixture and the second mixture cooperate with each other to synergistically enhance the skin elasticity R2 under the eyes and the canthus.

2.3 lower eyelid skin Melanin content MI value

The change rate of MI value of melanin content in the skin of the lower eyelid after 28 days of continuous use of the product is shown in table 29 below:

TABLE 29

As can be seen from the comparison among examples 1, 4 to 7 and comparative examples 1 to 2, squalane, meadowfoam seed oil, chamomile oil, neroli oil, the first mixture and the second mixture cooperate with each other to synergistically lower the MI value of the melanin content of the lower eyelid skin.

2.4 Mild testing

The test method comprises the following steps: refer to "cosmetic hygiene Standard" for testing patch on skin. 90 healthy, allergy-free, disease-insensitive, 90 volunteers aged 18 to 60 years were selected as subjects, which were divided into 9 groups of 10 persons each, using the full-effect eye creams provided in examples 1 to 7 and comparative examples 1 to 2, respectively. Other skin care products could not be used during the test. Selecting a spot tester with an area of 6mm multiplied by 6mm, putting a test object into a small chamber of the spot tester, wherein the dosage is 0.025g, sticking the spot tester with the test object on the back of a subject by using a hypoallergenic adhesive tape, and lightly pressing the spot tester with a palm to uniformly stick the spot tester on the skin for 24 hours. 30min (after the indentation disappears), 24h and 48h after the test object spot tester is removed. Skin reactions were observed according to the criteria shown in table 30 and the observations were recorded.

Watch 30

Grade of rating	Skin reactions
			0	Negative reaction
1	Suspicious reaction, only faint erythema
		2	Erythema, infiltrates, edema, and possibly pimples
3	Erythema, infiltration, edema, pimples, dragons; the reaction can exceed the tested area
		4	Obvious erythema, severe infiltration, edema, and fusional herpes; reaction beyond the variation zone

The test result shows that the grading grades of all groups are 0, and the total-effect eye cream provided by the invention is very mild and has no irritation to skin.

The applicant states that the process of the present invention is illustrated by the above examples, but the present invention is not limited to the above process steps, i.e. it is not meant to imply that the present invention must rely on the above process steps to be carried out. It will be apparent to those skilled in the art that any modification of the present invention, equivalent substitutions of selected materials and additions of auxiliary components, selection of specific modes and the like, which are within the scope and disclosure of the present invention, are contemplated by the present invention.

Claims

1. The full-effect eye cream is characterized by comprising, by mass, 40-60% of water, 0.5-2% of a first mixture and 10-30% of a second mixture;

2. The full-effect eye cream according to claim 1, wherein the first mixture comprises ZPC-019S and the second mixture comprises MAX-Peptide;

preferably, the full-effect eye cream further comprises 1-3% of a third mixture, 0.3-1% of hydrogenated lecithin, 1-3% of behenyl alcohol, 0.5-1.5% of C10-18 fatty acid triglyceride and 1-2% of polydimethylsiloxane by mass percentage;

preferably, the third mixture comprises Montanov L.

3. The full-effect eye cream as claimed in claim 1 or 2, which further comprises 1-3% of meadowfoam seed oil, 1-3% of squalane, 0.005-0.02% of ubiquinone, 0.3-0.6% of tocopherol acetate, 0.01-0.05% of sodium hyaluronate and 0.5-3% of glyceryl polyether-26 by mass percentage.

4. The full-effect eye cream according to any one of claims 1 to 3, further comprising 3 to 6% of glycerin, 0.005 to 0.03% of disodium EDTA, 0.05 to 0.2% of dipotassium glycyrrhizinate, and 0.1 to 0.3% of acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer, by mass percentage.

5. The full-effect eye cream as claimed in any one of claims 1 to 4, further comprising 0.5 to 1% of a fourth mixture, 0.1 to 0.15% of aminomethyl propanol, 0.1 to 0.3% of a fifth mixture, 2 to 3% of 1, 2-pentanediol, and 0.05 to 0.2% of a sixth mixture, in mass percentage;

the fifth mixture comprises 1, 2-hexanediol and octanediol;

68, the sixth mixture comprises a fully human source ^TM Collagen protein.

6. The full-effect eye cream as claimed in any one of claims 1 to 5, further comprising 0.2 to 0.5% of a seventh mixture, 0.001 to 0.003% of neroli oil, 0.005 to 0.12% of chamomile oil and 1 to 3% of an eighth mixture in terms of mass percentage;

said seventh mixture comprises water, 1, 3-propanediol, and saffron extract;

the eighth mixture comprises water, acetyl tetrapeptide-5, and butylene glycol;

peptide solution B。

7. Full-effect eye cream according to any one of claims 1 to 6, the full-effect eye cream comprises, by mass, 40-60% of water, 0.5-2% of a first mixture, 10-30% of a second mixture, 1-3% of a third mixture, 0.3-1% of hydrogenated lecithin, 1-3% of behenyl alcohol, 0.5-1.5% of triglyceride C10-18 fatty acid, 1-2% of polydimethylsiloxane, 1-3% of meadowfoam seed oil, 1-3% of squalane, 0.005-0.02% of ubiquinone, 0.3-0.6% of tocopherol acetate, 0.01-0.05% of sodium hyaluronate, 260.5-3% of glyceryl polyether, 3-6% of glycerol, 0.005-0.03% of disodium EDTA, 0.05-0.2% of dipotassium glycyrrhizinate, 0.1-0.3% of acrylic acid (ester)/C10-30 alkanol acrylate cross-polymer, 0.5-1% of a fourth mixture, 0.1-0.15% of aminomethyl propanol, 0.1-0.3% of a fifth mixture, 1, 2-3% of pentanediol, 2-3% of a sixth mixture, 0.05-0.1-0.003% of chrysanthemum flower oil, 0.1-0.003% of a seventh mixture, 0.1-0.003% of orange oil and 0.003% of a mixture;

the fifth mixture comprises 1, 2-hexanediol and octanediol;

said seventh mixture comprises water, 1, 3-propanediol, and saffron extract;

the eighth mixture comprises water, acetyl tetrapeptide-5, and butylene glycol;

preferably, the first mixture comprises ZPC-019S, the second mixture comprises MAX-Peptide, the third mixture comprises Montanov L, the fourth mixture comprises SEPIPLUS, and the fifth mixture comprises SEPIPLUS

peptide solution B。

8. A method for preparing the full-effect eye cream as claimed in any one of claims 1 to 7, wherein the method comprises the following steps:

9. The preparation method of claim 8, wherein the preparation method of the full-effect eye cream specifically comprises the following steps:

(1) Mixing the third mixture, hydrogenated lecithin, behenyl alcohol, triglyceride of C10-18 fatty acid, polydimethylsiloxane, chinaroot greenbrier seed oil, squalane, ubiquinone and tocopherol acetate, and stirring to obtain an oil phase;

10. The method according to claim 8 or 9, wherein in the step (1), the temperature of the stirring is 80-85 ℃ in the operation of obtaining the oil phase;

preferably, in the step (1), the temperature of the stirring is 80-85 ℃ in the operation of obtaining the water phase;

preferably, in the step (2), the temperature of the primary high-speed homogenizing and the temperature of the secondary high-speed homogenizing are respectively and independently 80-85 ℃, and the rotating speed is respectively and independently 2000-3000rpm;

preferably, in step (3), the temperature of the stirring is 44-46 ℃.